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Abstract 
 
Modulating the activity of the endocannabinoid system influences various gastrointestinal physiological and 
pathophysiological processes, and cannabinoid receptors as well as regulatory enzymes responsible for the 
synthesis or degradation of endocannabinoids represent potential targets to reduce the development of 
gastrointestinal mucosal lesions, hemorrhage and inflammation. Direct activation of CB1 receptors by plant-
derived, endogenous or synthetic cannabinoids effectively reduces both gastric acid secretion and gastric motor 
activity, and decreases the formation of gastric mucosal lesions induced by stress, pylorus ligation, nonsteroidal 
anti-inflammatory drugs (NSAIDs) or alcohol, partly by peripheral, partly by central mechanisms. Similarly, 
indirect activation of cannabinoid receptors through elevation of endocannabinoid levels by globally acting or 
peripherally restricted inhibitors of their metabolizing enzymes (FAAH, MAGL) or by inhibitors of their cellular 
uptake reduced the gastric mucosal lesions induced by NSAIDs in a CB1 receptor-dependent fashion. Dual 
inhibition of FAAH and cyclooxygenase induced protection against both NSAID-induced gastrointestinal damage 
and intestinal inflammation. Moreover, in intestinal inflammation direct or indirect activation of CB1 and CB2 
receptors exerts also multiple beneficial effects. Namely, activation of both CB receptors was shown to ameliorate 
intestinal inflammation in various murine colitis models, to decrease visceral hypersensitivity and abdominal pain, 
as well as to reduce colitis-associated hypermotility and diarrhea. In addition, CB1 receptors suppress secretory 
processes and also modulate intestinal epithelial barrier functions. Thus, experimental data suggest that the 
endocannabinoid system represents a promising target in the treatment of inflammatory bowel diseases, and this 
assumption is also confirmed by preliminary clinical studies. 
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1. INTRODUCTION 
 
Direct activation of cannabinoid receptors by plant-derived, endogenous and synthetic cannabinoids 
 
Cannabinoids were primarily discovered in marijuana (cannabis flower) and hashish (compressed 
cannabis resin) from the plant of Cannabis sativa [1]. This plant contains more than 80 phytocannabinoids [2]. 
The main active constituent of marijuana is the psychoactive ∆9-tetrahydrocannabinol (∆9-THC), which acts at 
cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors as a partial agonist. Other important natural cannabinoids 
present in marijuana are the non-psychoactive cannabidiol (CBD), ∆9-tetrahydrocannabivarin (∆9-THCV) and 
cannabichromene (CBC) [1-3]. Among them CBD has attracted the greatest attention thus far. It was shown to 
antagonize the effects of CB1/CB2 receptor agonists, to counteract the psychotropic and other negative effects of 
∆9-THC and several data suggest that it behaves as an inverse agonist of CB1 and CB2 receptors [4-6]. 
Some of these plant-derived cannabinoids are used in the medical praxis, such as ∆9-THC (dronabinol) 
and its synthetic analogue, nabilone against chemotherapy-induced nausea and emesis, and as appetite stimulants 
(e.g. in AIDS patients), and CBD combined with ∆9-THC (nabiximols) to relief neuropathic pain and spasticity in 
multiple sclerosis, and as an adjunctive analgesic treatment in advanced cancer pain [7]. 
Besides phytocannabinoids another group of naturally occurring substances that interact with cannabinoid 
receptors are the endocannabinoids. These lipid mediators are not stored but synthesized on demand in a site- and 
time-dependent manner and are rapidly degraded after exerting a transient and localized effect [8]. Interestingly, 
discovery of cannabinoid receptors preceded the isolation of their endogenous ligands, the endocannabinoids. 
Namely, while CB1 receptor was isolated in 1988 and cloned in 1990 [9, 10], the first endocannabinoid, N-
arachidonoylethanolamine or anandamide (AEA) was isolated from the porcine brain only in 1992, and it showed 
high binding affinity to the brain CB1 receptor [11]. CB2 receptor was cloned in 1993 [12] and the second 
endocannabinoid, 2-arachidonoylglycerol (2-AG) was identified in 1994 - 1995 [13, 14]. Since then further 
endogenous cannabinoids have been identified, such as homo-γ-linolenoylethanolamine, 7,10,13,16-
docosatetraenoylethanolamide, 2-arachidonoylglycerol ether (2-AGE, noladin ether), O-arachidonoyl 
ethanolamine (virodhamine) and N-arachidonoyl dopamine (NADA) (see review [15]). 
Synthetic cannabinoid derivatives may differ from the natural ones in several aspects, e.g. in 
pharmacokinetic properties or in binding affinity to the different cannabinoid receptors. For example 
methanandamide, an amidase resistant chiral analogue of AEA [16] possesses higher metabolic stability than its 
parent compound. WIN 55,212-2, an aminoalkylindole derivative is a potent agonist at both CB1 and CB2 receptors 
and one of the most frequently used synthetic cannabinoids. It produces effects similar to those of ∆9-THC, 
although it has an entirely different chemical structure [17, 18]. Differences in binding affinity to different 
cannabinoid receptors may result in selective agonists at CB1 or CB2 receptors. For example, ACEA (arachidonyl-
2'-chloroethylamide) is selective for CB1 receptors [19], while JWH 133 (3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-
THC) [20] or GP1a (1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazo le-3-
carboxamide) [21] for CB2 receptors. Moreover, differences in distribution may result either in global actions or 
peripherally restricted effects, such as the peripherally acting CB1/2 agonist AZD 1940 and AZD 1704 developed 
by Astra Zeneca (see review [22]). 
Besides cannabinoid CB1 and CB2 receptors, endogenous cannabinoids and synthetic derivatives can act 
on other receptors as well. For example, AEA, its synthetic analogue methanandamide as well as the AEA uptake 
inhibitor AM404 (N-arachidonoylaminophenol, see later) activate TRPV1 receptor, and AEA and various 
synthetic cannabinoids can also act on central putative non-CB1, non-CB2, non-TRPV1 receptors, putative non-I1, 
non-I2 imidazoline receptors and allosteric sites on muscarinic M1 and M4 receptors and on 5-HT3 receptors (see 
review: [23]). 
 
Indirect activation of cannabinoid receptors by inhibition of endocannabinoid metabolism or uptake 
 
Activation of CB1 and CB2 receptors can be achieved not only directly by the natural and synthetic 
cannabinoids, but also indirectly, by elevation of the level of endocannabinoids in the vicinity of cannabinoid 
receptors, either by blocking their degradation or uptake. AEA and 2-AG levels are regulated in vivo by catabolic 
enzymes, like the intracellular fatty acid amide hydrolase (FAAH), which hydrolyzes AEA into arachidonic acid 
and ethanolamine [24], and monoacylglycerol lipase (MAGL) [25], which is the main contributor to 2-AG 
hydrolysis. However, additional enzymes - cyclooxygenases (COX), lipooxygenases and cytochrome P450 
enzymes - may also have role in the degradation of endocannabinoids [26]. Moreover, both AEA and 2-AG are 
removed from the extracellular space by a process of cellular uptake (and metabolism); however the transporter 
involved in this uptake mechanism has not yet been cloned [27-29]. 
Pharmacological blockade of the degradation of endocannabinoids is an attractive strategy for enhancing 
endocannabinoid signaling. It is supposed that increasing endocannabinoid tissue levels would induce less 
psychoactive effects (such as catalepsy, hypothermia, or hyperphagia) than the direct stimulants of CB1 receptors 
[30], while the beneficial effects due to activation of CB1 and/or CB2 receptors would be retained [31]. However, 
it also has to be considered that inhibitors of the degradation or uptake are not entirely selective for 
endocannabinoids, e.g. FAAH hydrolyzes not only AEA, but also other bioactive lipids, such as N-palmitoyl-
ethanolamine and oleamide [32, 33], and the AEA uptake inhibitor AM404 also activates TRPV1 receptor and 
inhibits COX-1 and COX-2 enzymes [34, 35]. 
Several FAAH inhibitors have been developed [36], among which the most widely used is URB 597, an 
irreversible inhibitor of FAAH both in the CNS and in the periphery [37, 38]. URB 937, an O-aryl carbamate 
derivative, is also a potent FAAH inhibitor, but it is extruded from the CNS by membrane transporter ATP-binding 
cassette, thus it inhibits the inactivation of AEA only in peripheral tissues [39]. Recently, the first class of 
systemically active multitarget FAAH/COX inhibitors has been developed. The class prototype ARN2508 is a 
potent inhibitor of FAAH, as well as of COX-1, and COX-2 enzymes [40]. 
The development of FAAH inhibitors was later followed by the introduction of selective MAGL 
inhibitors. In 2009 Long et al. published [41] that JZL 184 (4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-
yl(hydroxy)methyl)piperidine-1-carboxylate) irreversibly, selectively inhibits MAGL, and elevates the brain level 
of 2-AG by 8-fold without affecting the level of AEA. 
However, when analyzing the biological actions of the degradation inhibitors of endocannabinoids it 
should be considered that elevation of the tissue levels of endocannabinoids may increase the formation of 
cyclooxygenase-, lipoxygenase- and cytochrome P450-derived metabolites, which are bioactive and may have 
pro-inflammatory properties as well, such as prostamide F2α [26, 42, 43]. 
Besides inhibition of degradation, another way to increase the level of endocannabinoids is to interfere 
with their cellular uptake mechanism. AM404 is an AEA analogue and the active metabolite of paracetamol [44], 
which is the best characterized AEA uptake inhibitor in vivo. It inhibits the carrier-mediated transport of AEA into 
presynaptic neurons and other related compounds back from the synaptic cleft without affecting AEA hydrolysis 
[45]. As mentioned above, it is also an inhibitor of COX-1 and COX-2 enzymes and an agonist on TRPV1 receptors 
[34, 35]. VDM11, an AEA derivate, is as potent membrane transporter inhibitor as AM404, but it has no agonistic 
activity at TRPV1 receptors and is a weaker CB1 receptor agonist than AM404 [34]. 
Originally definitive differences in distribution of CB1 and CB2 receptors have been suggested. While 
CB1 receptors have been shown to be widely distributed throughout the central, peripheral and enteric nervous 
system [1], CB2 receptors were thought to be located peripherally mainly in the immune tissues (spleen and 
macrophages) [46]. However, recent finding suggest functionally relevant expression of CB2 receptors in specific 
regions of the brain, such as in primed microglia [47] and in neurons in the brainstem [48]. Moreover, this subtype 
was also shown in several peripheral non-immune tissues, e.g. in myocardium, gut, endothelial, vascular smooth 
muscle, pancreas, bone, reproductive organs/cells, and in different tumors [49]. Furthermore, inflammation or 
tissue injury results in increase of local endocannabinoid levels and changes in CB2 receptor expressions. Such 
alteration was observed not only experimentally but also in several human diseases, for example in cardiovascular, 
gastrointestinal, kidney, neurodegenerative, psychiatric, bone, skin, autoimmune and pulmonary disorders (see 
review [49]). 
 
2. GASTROINTESTINAL ACTIONS OF CANNABINOIDS 
Modulating the activity of the endocannabinoid system (ECS), which comprises CB1 and CB2 receptors, 
the endocannabinoids and their synthetic and metabolizing enzymes, may have therapeutic potential in numerous 
diseases including obesity/metabolic syndrome, diabetes, neurodegenerative, inflammatory, cardiovascular and 
psychiatric disorders, liver and skin diseases, pain, cachexia, cancer, as well as chemotherapy-induced 
nausea/vomiting (see review of [22]). 
The role of ECS in the physiology and pathophysiology of gastrointestinal (GI) tract has also been 
extensively studied [50-54]. In the digestive tract high levels of the endocannabinoids, and of the enzymes 
responsible for their synthesis and metabolism can be detected. The presence of CB1 receptors on myenteric and 
submucosal nerve plexuses along the alimentary tract has been shown by immunohistochemical studies (see review 
of [55]). Co-localization of CB1 receptor with the cholinergic marker choline acetyltransferase in neural elements 
innervating smooth muscle, mucosa and submucosal blood vessels of rat stomach fundus, corpus and antrum was 
shown [56]. 
There is a number of evidence that activation or inhibition of peripheral (e.g. via enteric neurons) and/or 
central (vagal, brainstem and spinal nerves) cannabinoid receptors may substantially influence the physiological 
and pathophysiological processes of the GI tract. 
The aims of this review are 1) to summarize the effects of cannabinoids on gastric functions (i.e. on gastric 
acid secretion, gastric motor activity and emptying, as well as on gastric mucosal integrity), and 2) to provide an 
overview of current knowledge on the cannabinoid receptor-mediated beneficial effects in inflammatory bowel 
diseases (IBDs). 
 
2.1. EFFECTS OF CANNABINOIDS ON GASTRIC FUNCTIONS 
 
Cannabinoids and gastric acid secretion 
 
Data of the literature suggest that cannabinoids inhibit gastric acid secretion. The antisecretory effect of 
cannabinoids (non selective CB-receptor agonist WIN 55,212-2 and the selective CB1-receptor agonist HU-210 
given intravenously /i.v./) in the rat was shown to be related to suppression of the vagal drive to the stomach. This 
effect was mediated by CB1 receptors located on pre- and postganglionic cholinergic neurons [56]. While bilateral 
cervical vagotomy significantly reduced, but not abolished the antisecretory action of synthetic cannabinoids, 
atropine failed to modify it. These findings suggest that the release of non-cholinergic excitatory neurotransmitters 
may be regulated by CB1 receptors [56]. Moreover, since the CB-receptor agonist given intracerebroventricularly 
(i.c.v.) failed to affect the acid output, it may be concluded that inhibition of gastric acid secretion in the rat is 
mainly peripherally located [57]. Interestingly, in contrast with the in vivo data, in isolated gastric fundus synthetic 
cannabinoids (WIN 55,212-2 and HU-210) did not change the basal or stimulated acid output to histamine, 
pentagastrin or electrical field stimulation [58]. 
Cannabinoids and gastric motor activity and emptying 
The psychoactive major constituents of marijuana and the synthetic cannabinoid nabilone were 
demonstrated to slow the rate of gastric emptying in mice and rats, however, the non-psychoactive CBD given 
intravenously (i.v.) failed to affect it [59]. In contrast, both psychoactive and non-psychoactive cannabinoid 
agonists were found to delay gastric emptying through activation of cannabinoid CB1 receptors. Since neither CB1 
nor CB2 receptor antagonists affected gastric emptying alone, endogenous cannabinoid system does not seem to 
modulate gastric motor activity tonically [60]. 
Δ9-THC exerted inhibitory effect on gastric motility and emptying and this effect was abolished by 
bilateral cervical vagotomy, suggesting the involvement of a central component (the dorsal vagal complex) in the 
observed effect. It was supposed that cannabinoids modulate the vagal (parasympathetic) outflow to gastric smooth 
muscle [61]. Furthermore, i.c.v. administration of WIN 55,212-2 inhibited the gastric emptying in rats [62]. 
However, i.c.v. injection of the CB1 receptor antagonist SR141716A failed to affect the inhibitory action of 
peripherally injected WIN 55,212-2, which argues against the role of central cannabinoid receptors and suggests 
that peripheral CB1 receptors are primarily responsible for the inhibition of gastric emptying [62]. 
Several studies aimed to clarify whether tolerance develops to the inhibitory effect of GI motor activity 
of cannabinoids. Based on in vivo and in vitro studies in mice and guinea pigs it was concluded that cannabinoid 
pretreatment induces tolerance to the inhibitory actions of cannabinoid receptor agonists on GI motility (see review 
of [63]). However, Abalo et al. (2011) found that after chronic intermittent administration of WIN 55,212-2 to the 
rat its inhibitory effect on gastric emptying was intensified, indicating that hypersensitization may develop to some 
of the effects of cannabinoids, particularly to the delayed gastric emptying [64]. 
Cannabinoids and gastric mucosal integrity 
CB1 and CB2 receptors and enzymes involved in regulation of synthesis and degradation of 
endocannabinoids are all potential targets, which can be modulated to protect the gastric mucosa against erosions, 
mucosal lesions and inflammation (Table 1). 
Activation of cannabinoid receptors by exogenous or endogenous ligands has been shown to decrease the 
formation of different types of experimental gastric ulcers. For example Δ9-THC reduced mucosal damage induced 
by pylorus ligation [65]. It also attenuated diclofenac-induced gastric mucosal lesions given either orally or 
intraperitoneally (i.p.) in a CB1 receptor-dependent fashion, and it proved to be more potent in exerting 
gastroprotective effect than producing classical cannibimimetic effects, such as locomotor immobility, 
antinociception, hypothermia and catalepsy [66, 67]. Gastric lesions induced by water immersion and restraint 
stress were reduced by AEA as well as by WIN 55,212-2 (both given i.p.), and their gastroprotective action was 
mediated also by CB1 receptors [68, 69]. The protective effect of AEA was associated with an increase in gastric 
mucosal blood flow and mucosal DNA synthesis and with reduced level of pro-inflammatory interleukin-1β (IL-
1β) [69]. Involvement of CB1 receptors in gastroprotection was further supported by the results with the selective 
cannabinoid CB1 receptor agonist ACEA, which effectively reduced the aspirin-induced gastric mucosal lesions 
(given i.p.) [70]. 
As discussed above, cannabinoids inhibit also gastric acid secretion via CB1 receptors. Acid secretion is 
involved in the pathomechanism of gastric damage induced by pylorus ligation, cold restraint test as well as in 
NSAID-induced mucosal damage. According to the original concept, cytoprotective (gastroprotective) effect was 
unrelated to inhibition of acid secretion, and acid-independent ulcer models induced by absolute ethanol, 0.6 N 
hydrochloric acid, 0.2 N sodium hydroxide and 25% sodium chloride were used to demonstrate the cytoprotective 
effect of prostaglandins [71]. Cannabinoids, such as AEA, methanandamide and WIN 55,212-2, have been shown 
to reduce the absolute ethanol-induced gastric lesions after both peripheral (i.v.) and central (i.c.v.) administration 
in the rat by a CB1 receptor-mediated mechanism [72]. Moreover, the role of endogenous opioids (endomorphin 
2) was suggested by the findings that the gastroprotective effect of AEA was antagonized by naloxone and by 
pretreatment with endomorphin 2 antiserum [72]. Involvement of a central component in the gastroprotective 
action of cannabinoids was confirmed by the findings that the protective effect of methanandamide injected i.v. 
was reversed by i.c.v injected SR141716A, a CB1 receptor antagonist [72]. 2-AG prevented also ethanol-induced 
lesions, when given i.c.v. in the rat. Moreover, 2-AG was shown to be involved in the centrally initiated 
gastroprotective effect of angiotensin II, which was reversed by the CB1 receptor antagonist/inverse agonist AM 
251, as well as by tetrahydrolipstatin, an inhibitor of diacylglyceol lipase (DAGL), the principle enzyme 
responsible for the synthesis of 2-AG [73]. 
As described above, the cannabinoid system can be activated not only by direct stimulation of 
cannabinoid receptors, but also via the inhibition of enzymes that inactivate the endocannabinoids. Inhibition of 
FAAH by URB 597 resulted in inhibition of diclofenac-induced gastric mucosal lesions. Similarly, reduction of 
the mucosal lesions was observed in transgenic, FAAH (-/-) mice. URB 597 retained its efficacy in CB2 (-/-) mice, 
but was ineffective in CB1 (-/-) mice, indicating that the gastroprotective effect was mediated entirely by CB1 
receptors [74]. 
In contrast to URB 597, which is a global FAAH inhibitor, URB 937 inhibits FAAH only in peripheral 
tissues. It reduced the gastric lesions induced by indomethacin. It also exerted antinociceptive and anti-
inflammatory activity and its combination with indomethacin synergistically attenuated pain-related behaviors 
[75]. 
Recently, compounds that block both FAAH and COX enzymes have been developed. The hypothesis 
was that multitarget FAAH/COX blockade may result in substantial anti-inflammatory efficacy and decrease of 
gastrointestinal toxicity [40]. Namely, it is well-documented that COX-2 has pathogenetic role in inflammatory 
processes. On the other hand, increased FAAH-mediated degradation of AEA was observed in some inflammatory 
conditions [76]. Since several data suggest the anti-inflammatory and mucosal protective effect of AEA, reduction 
of its level by increased FAAH activity may weaken its ability to attenuate the inflammation and gastrointestinal 
injury. Data of the literature suggest that both COX-2 [77] and FAAH are expressed at abnormally high levels [78, 
79] in IBD and increased COX-2 activity in gastrointestinal mucosa may mediate not only protective actions but 
also formation of bioactive metabolites and inflammatory mediators generated by COX-2-dependent oxygenation 
of AEA, such as prostamide F2α [26]. The prototype of ligands that target FAAH, COX-1, and COX-2 is 
ARN2508, which besides exerting profound inhibition of dextran sulfate sodium (DSS) and 2,4,6-trinitrobenzene 
sulfonic acid (TNBS)-induced colitis (see also below), did not cause gastric mucosal injury and protected the 
stomach from the damaging effect of flurbiprofen through a mechanism that requires FAAH inhibition and 
elevation of AEA level [40]. These results suggest that FAAH/COX blockade may provide a new therapeutic 
strategy for the treatment of inflammatory diseases in which both enzymes are overactive. 
Elevating the level of the other principle endocannabinoid, 2-AG by inhibiting MAGL with JZL 184 also 
induced significant protection and reduced the diclofenac-induced gastric hemorrhages injected i.p. to the mouse. 
JZL184 increased significantly the gastric levels of 2-AG, but did not influence that of AEA, free arachidonic acid, 
PGE2, or PGD2 suggesting that prostaglandins are not involved in the protective action of MAGL inhibitiors 
against NSAID-induced gastric ulcers. It was found that the protective effect may be related to the reduction of 
diclofenac-induced elevation of proinflammatory cytokines, such as IL-1β, IL-6 or tumor necrosis factor-α (TNF-
α). Pharmacological or genetic blockade of CB1, but not CB2 receptors inhibited the protective effect of JZL 184, 
which again indicates the predominant role of CB1 receptors in the regulation of gastric mucosal integrity [67]. 
Table 1. Gastric mucosal protective effect of direct and indirect stimulants of cannabinoid receptors 
Compound Target 
within the 
ECS 
Ulcer model Route of 
administration, 
animal 
Antagonist 
or genetic 
manipulation 
to clarify the 
CB receptor 
type 
Receptor 
type that 
mediates 
the 
effect 
Reference 
Δ9-THC  CB1, 
CB2 
 
pylorus 
ligation 
 
rat 
 
 
 
not 
detected 
 
Sofia et al. 
[65] 
Δ9-THC CB1, 
CB2 
 
diclofenac i.p., per os, 
mouse 
CB1, CB2 
2 antagonist, 
deletion of 
CB1, CB2 
receptors 
 
CB1 Kinsey and 
Cole [66], 
Kinsey et al. 
[67] 
WIN 55,212-2 
 
CB1, 
CB2 
 
water 
immersion 
restraint 
stress 
i.p., rat 
 
CB1, CB2 
antagonist 
 
CB1 Germano et 
al. [68] 
AEA CB1, 
CB2 
 
water 
immersion 
i.p., rat CB1 
antagonist 
 
CB1 Dembinski 
et al. [69] 
restraint 
stress 
ACEA CB1 aspirin i.p., rat  CB1 Rutkowska 
and 
Fereniec-
Goltbiewska 
[70] 
AEA, 
methanandamide, 
WIN 55,212-2 
CB1, 
CB2 
100% 
ethanol 
i.v., i.c.v., rat CB1 
antagonist 
CB1 Shujaa et al. 
[72] 
2-AG 
 
CB1, CB2 100% 
ethanol 
i.c.v., rat CB1 
antagonist 
 
CB1 Gyires et al. 
[73] 
URB 597 FAAH 
inhibition 
(both 
centrally and 
peripherally) 
diclofenac i.p., mouse  deletion of 
CB1 and CB2 
receptors 
CB1 Naidu et al. 
[74] 
URB 937 FAAH 
inhibition 
(only 
peripherally) 
indomethacin p.os, mouse  not 
analyzed 
Sasso et al. 
[75] 
ARN2508 FAAH, 
COX-1, 
COX-2 
inhibition 
flurbiprofen 
(DSS, TNBS 
colitis) 
p.os, mouse CB1 
antagonist 
CB1 Sasso et al. 
[40] 
JZL 184 MAGL 
inhibition 
diclofenac p.os, i.p., 
mouse  
deletion of 
CB1 and CB2 
receptors 
CB1 Kinsey et al. 
[67] 
Abbreviations: 2-AG: 2-arachidonoylglycerol; AEA: anandamide; COX: cyclooxygenase; ECS: endocannabinoid 
system; FAAH: fatty acid amide hydrolase; i.c.v.: intracerebroventricularly; i.p.: intraperitoneally; i.v.: 
intravenously; MAGL: monoacylglycerol lipase; p.os: orally 
 
II.2. CANNABINOIDS IN INFLAMMATORY BOWEL DISEASES 
Inflammatory bowel diseases (IBDs) are chronic, relapsing inflammatory conditions of the 
gastrointestinal (GI) tract. The two major forms are Crohn’s disease (CD) and ulcerative colitis (UC), which share 
similar symptoms, such as diarrhea, abdominal pain and weight loss [80]. The pathogenesis of both forms is 
complex, involving various predisposing environmental and genetic factors, which together with the altered 
intestinal flora can induce mucosal disruption and result in penetration of luminal antigens into the gut wall [73, 
80].[80, 81] The activation of immune cells by these antigens and the chronic, uncontrolled inflammation is a key 
component of the pathogenesis of IBDs, and the patients are mainly treated today with anti-inflammatory and 
immunosuppressive agents, such as 5-aminosalicylic acid derivatives, corticosteroids, purine antimetabolites, 
methotrexate, calcineurin inhibitors or monoclonal antibodies targeting primarily TNF-α [81]. The long-term use 
of these medications, however, can induce severe adverse reactions, and a large effort is currently put into finding 
new therapeutic approaches [73][81]. Beside developing new antibodies targeting various anti-inflammatory 
cytokines and attempting to restore the altered microbiota, one promising approach is the activation of cannabinoid 
receptors in the gut, which does not only suppresses many of the IBD-related symptoms, such as diarrhea and 
visceral hypersensitivity, but also inhibits the inflammatory reaction. 
 
The endocannabinoid system in healthy and inflamed gut 
 
All components of the ECS (CB1 and CB2 receptors, the endocannabinoids AEA and 2-AG, and proteins 
responsible for their synthesis and degradation) are widely distributed in the GI tract, and there is plenty of 
evidence that their expression is substantially altered during inflammation. 
Both CB receptors are localized throughout the gut. In non-inflamed tissues CB1 receptors are mainly 
localized on excitatory motor neurons, interneurons and intrinsic primary afferent neurons of the enteric nervous 
system (ENS), although epithelial cells, smooth muscles and immune cells express also this subtype [82-84]. CB2 
receptors, on the other hand, are mainly expressed by subepithelial immune cells (such as macrophages and plasma 
cells) [82], and also by enteric neurons [85, 86], while they are absent in epithelial cells [82, 85]. 
As described in the introduction, AEA and 2-AG are synthesized on-demand from membrane lipid 
precursors [87], and their primary biosynthetic enzymes, N-acylphosphatidylethanolamine selective phospholipase 
D (NAPE-PLD) and diacylglycerol lipase (DAGL)-α and -β, respectively, have been identified in the small and 
large intestines of mice and humans [78, 79, 83, 88, 89]. Immunohistochemical studies revealed that both synthetic 
enzymes are localized in the epithelium, in lamina propria plasma cells, in both layers of muscularis externa and 
in nerve fibers of the myenteric plexus [78, 83], suggesting an active endocannabinoid synthesis in the healthy gut. 
Accordingly, 2-AG and (in considerably lower amount) AEA have been demonstrated in the intestines of different 
species [79, 90-92]. 
The endocannabinoids are subjected to various degradation pathways [87], and the major enzymes 
responsible for their hydrolysis, FAAH (AEA) and MAGL (2-AG) show similarly wide GI distribution [83, 90, 
93, 94]. 
The concept that the ECS is altered in IBD is supported by several animal and human studies, and Tables 
2 and 3 provide a brief overview of the observed changes. At the first glance these results are rather contradictory, 
since both elevated, depressed and unchanged expressions of the various components have been described, but a 
closer look reveals some important similarities. 
In the majority of studies, the expression of CB1 receptor was elevated in the inflammed gut, and this was 
evident in both epithelial cells, lamina propria mononuclear cells and myenteric neurons [79, 95, 96]. Although in 
the case of CB2 receptor the findings are more erratic, an increased epithelial expression has been consistently 
observed [82, 83, 96]. These findings suggest that disruption of the epithelial barrier and the concomitant 
inflammatory reaction upregulate the expression of both CB receptors, which may explain the enhanced GI effects 
of CB receptor ligands in inflammation (see below). 
Among the endocannabinoids the intestinal level of AEA during inflammation almost always differed 
significantly from the level measured in healthy tissues, however, both elevation [92, 93] and reduction [40, 79, 
89] have been reported. These diverging results can be partly explained by different experimental conditions. For 
example, the measured levels of AEA and its synthetic and degrading enzymes seem to vary at different time 
points during the course of the disease. Storr et al. [97] observed significantly reduced FAAH mRNA in the early 
phase of various colitis models (TNBS, oxazolone, DSS), but this reduction disappeared at later time points, or 
even changed to an elevation. This finding suggests that the level of AEA increases in the initial phase of colitis, 
which may have important protective effect, but with the progression of the disease this endogenous protective 
mechanism deteriorates. Beside this time-dependence AEA levels also differ in various segments of the gut, as 
well as in different regions of the gut wall. For instance, Izzo et al. [89] reported a significant decrease of AEA 
level in the jejunum of croton oil-treated mice, but not in the duodenum or ileum, and in the study of D’Argenio 
et al. [92] TNBS-treatment induced significant rise of AEA in the submucosa, but not in the mucosa of rat colon. 
In short, these studies clearly demonstrate that intestinal inflammation alters the tissue level of AEA, but further 
studies are needed to get a clear picture of its role in the pathomechanism. 
Interestingly, the intestinal level of 2-AG in most studies remained unchanged [79, 91, 92, 98], which 
implies that this endocannabinoid does not have important role in IBD. An alternative explanation, however, can 
be that both the synthesis and degradation of 2-AG accelerate in inflammation, which results in a more rapid 
turnover without altering its tissue level. This assumption is supported by the findings of Marquez et al. [83], who 
measured elevated DAGL-α and MAGL levels in colon mucosal biopsies of patients with UC. 
In conclusion, both CB receptors and at least one of the two major endocannabinoids (AEA) show altered 
intestinal levels in IBD. The upregulation of CB receptors and their activation by AEA and 2-AG promotes 
epithelial healing and tempers the inflammation, as discussed below. This seems to be a systemic (pan-intestinal) 
reaction rather than a local response, because alterations were also observed in such parts of the gut, which were 
not directly exposed to the inflammatory agents [97]. Thus, the ECS may serve as an endogenous gastrointestinal 
defense system, which shows increased activity in pathological conditions and its impaired function may increase 
susceptibility to various GI diseases, such as IBD. This is in line with findings that genetic deletion or 
pharmacological blockade of either CB1 or CB2 receptors aggravates the development of murine colitis, while 
deletion of FAAH confers protection [95, 99, 100]. 
Unfortunately human studies failed to identify major IBD susceptibility genes related to the ECS so far, 
since the investigated single nucleotid polymorphisms (SNPs), such as the G1359A SNP (rs1049353) within the 
CNR1 gene encoding the CB1 receptor [101], the Q63R SNP (rs35761398) in the CNR2 gene [102] or the FAAH 
C385A variant (rs324420) [97, 100] had only minor influence at best on the pathogenesis of IBD. These gene 
variants were also not identified as IBD susceptibility loci by recent genome-wide association studies [103]. 
 
Table 2. Altered ECS in animal models of IBD 
 
Animal Model CB1 CB2 AEA 2-
AG 
FAAH MAGL Reference 
C57BL/6N 
mouse 
DNBS ↑      Massa et al. 
[95] 
C57BL/6 mouse TNBS ↔ ↔  ↔ ↓ 
mRNA 
↓ 
mRNA 
Alhouayek 
et al. [98] 
↔ 
activity 
↔ 
activity 
CD1 mouse DSS ↑    ↑ ↑ Matos et al. 
[104] 
C57BL/6N 
mouse 
TNBS 
DSS 
 ↑     Storr et al. 
[105] 
ICR mouse croton oil ↑ ↓ ↓ ↔ ↓  Izzo et al. 
[89] 
ICR mouse croton oil ↑  ↔ ↔ ↑  Izzo et al. 
[91] 
CD1 mouse 
 
BALB/c mouse 
oil of 
mustard 
DSS 
↑ ↑     Kimball et 
al. [96] 
Sprague-Dawley 
rat 
LPS  ↔     Duncan et 
al. [86] 
CD1 mouse TNBS   ↓    Sasso et al. 
[40] 
Wistar rat 
C57BL/6J 
mouse 
TNBS 
DNBS 
  ↑ ↔   D'Argenio et 
al. [92] 
ICR mouse DNBS   ↑ ↑ ↓  Borrelli et 
al. [93] 
C57BL/6N 
mouse 
TNBS 
oxazolone 
DSS 
    ↓ / ↔  Storr et al. 
[97] 
C57BL/6 mouse TNBS 
DSS 
  ↑    Alhouayek 
et al. [33] 
C57BL/6 mouse TNBS    ↔   Salaga et al. 
[106] 
 
Signs and abbreviations: ↑: elevation, ↓: reduction, ↔: no change, 2-AG: 2-arachidonoylglycerol; AEA: 
anandamide; FAAH: fatty acid amide hydrolase; LPS: lipopolysaccharide; MAGL: monoacylglycerol lipase 
 
Table 3. Altered ECS in IBD patients 
 
IBD 
type 
CB1 CB2 AEA 2-
AG 
NAPE-
PLD 
DAGL-α 
and -β 
FAAH MAGL Reference 
CD, 
UC 
↑ ↔       Stintzing et 
al. [107] 
UC ↔ ↑   ↓ ↑ (α) 
↔ (β) 
↔ ↑ Marquez et 
al. [83] 
CD, 
UC 
↑ ↔ ↓ ↔ ↓  ↑  Di Sabatino 
et al. [79] 
UC   ↑ ↔     D'Argenio 
et al. [92] 
UC     ↔ 
(mRNA) 
↓ (protein) 
 ↑ 
(mRNA) 
↔ 
(protein) 
 Suarez et 
al. [78] 
CD, 
UC 
      ↔ (↓) *  Salaga et 
al. [106] 
Signs and abbreviations: ↑: elevation; ↓: reduction; ↔: no change; 2-AG: 2-arachidonoylglycerol; AEA: 
anandamide; DAGL: diacylglycerol lipase; FAAH: fatty acid amide hydrolase; MAGL: monoacylglycerol 
lipase; NAPE-PLD: N-acylphosphatidylethanolamine selective phospholipase D 
* FAAH mRNA levels showed tendency for reduction, but the difference did not reach statistical significance. 
 
The beneficial effects of cannabinoids in IBD 
 
Cannabis has been used for centuries to alleviate the symptoms of numerous diseases [108] and recent 
preliminary clinical studies (retrospectal observations, questionnaires and pilot prospective studies) confirmed the 
anecdotal reports that it may have beneficial effect in IBD as well [109-112]. In these studies the use of cannabis 
reduced the patients’ disease activity index, abdominal pain, diarrhea and improved their quality of life. 
In the last decade several experiments have been conducted to analyze the effects of cannabinoids in IBD, 
mainly by using different colitis models in animals, and the data accumulated thus far indicate that cannabinoids 
efficiently inhibit the inflammatory reaction, modulate the mucosal barrier functions and also alleviate some IBD-
associated symptoms, like diarrhea and visceral pain [82, 95, 96, 113-118]. 
 
Inhibition of inflammation 
 
There is a large body of evidence that cannabinoids exert immunomodulatory, mainly 
immunosuppressive effect. Both synthetic CB receptor agonists and endocannabinoids were shown to impair 
cellular and humoral immunity by reducing inflammatory cell recruitment, inducing T cell apoptosis and 
suppressing the production of numerous pro-inflammatory cytokines and chemokines (e.g. TNF-α, IL-1β, IL-2, 
IL-6, IL-17, IFN-γ, CCL2 or CXCL10) (recently reviewed by Turcotte et al. [119]). These effects are primarily 
mediated by CB2 receptors localized on macrophages and lymphocytes, but some studies underline the importance 
of CB1 receptors as well [95, 99, 120]. Furthermore, other, non-cannabinoid receptors, like peroxisome 
proliferator-activated receptor gamma (PPAR-γ) [121, 122] or adenosine A2A receptor [123] are also involved in 
the anti-inflammatory action of certain cannabinoids, like WIN 55,212-2 or CBD. Some phytocannabinoids, such 
as CBD and cannabigerol (CBG), as well as the endocannabinoid AEA also activate TRPV1 receptors [15, 124], 
but it is still a matter of debate whether this results in pro- or anti-inflammatory action. Namely, it was reported 
that AEA can induce intestinal inflammation by activating TRPV1 receptors [125] and antagonists of this receptor 
attenuate the development of DSS colitis [126], but there is also evidence that the presence of these receptors 
confers protection in dinitrobenzene sulfonic acid (DNBS) colitis [127]. 
Due to the complex anti-inflammatory action cannabinoids can efficiently inhibit the development of 
colitis. Table 4 provides a list from different non-selective and selective CB1 and CB2 receptor agonists, which 
proved to be protective in animal models of IBD. In general, these studies demonstrated that cannabinoids given 
peripherally significantly reduce the animals weight loss and diarrhea, the macroscopic and histological colonic 
damage, neutrophil migration and MPO activity, as well as the production of various inflammatory cytokines (like 
TNF-α or IL-1β). The protective effect was counteracted by pharmacological or genetic blockade of CB1 [95, 128] 
or CB2 receptors [105, 114], confirming the involvement of both receptors in the action. 
In most studies cannabinoids were given prophylactically, i.e. starting before or at the time of the colitis 
induction. Kimball et al. [96], however, demonstrated that ACEA was equally effective, while JWH-133 was even 
more effective, when administered therapeutically, that is 24 h after the colitis induction. Similarly, the covalently 
acting non-selective CB receptor agonist AM841 significantly attenuated DSS-induced inflammation, when it was 
given on days 4 – 7 after colitis induction [128]. These results indicate that cannabinoids can not only inhibit the 
development of colitis, but also able to effectively reduce the already established inflammation, which is in line 
with the observations in IBD patients. 
 
Table 4. Direct activation of CB1, CB2 or both receptors alleviate murine colitis 
 
Animal Colitis model Cannabinoid 
ligand 
CB receptor 
selectivity 
Dosage and 
route of 
administration 
Reference 
C57BL/6N 
mouse 
DNBS HU 210 non-selective 0.05 mg/kg, 
q.d., s.c. 
Massa et al. [95] 
CD1 mouse DSS 
TNBS 
AM 841 non-selective 0.01 – 1 mg/kg, 
q.d./b.i.d., i.p. 
Fichna et al. 
[128] 
AKR mouse TNBS AEA non-selective 5 mg/kg, q.d., 
i.p. 
Engel et al. 
[129] 
Wistar rat TNBS THC non-selective 10 – 20 mg/kg, 
q.d., i.p. 
Jamontt et al. 
[130] 
CD1 mouse DSS 
TNBS 
WIN 55,212-2 non-selective 2 mg/kg, b.i.d., 
i.p. 
Cluny et al. 
[131] 
C57BL/6J 
mouse 
DSS WIN 55,212-2 non-selective 5 mg/kg, q.d., 
i.p. 
Li et al. [132] 
CD1 mouse 
 
BALB/c mouse 
oil of mustard 
 
DSS 
ACEA CB1 2.5 mg/kg, 
q.d., i.p. 
10 mg/kg, 
b.i.d., i.p. 
Kimball et al. 
[96] 
CD1 mouse 
 
BALB/c mouse 
oil of mustard 
 
DSS 
JWH-133 CB2 2.5 mg/kg, 
q.d., i.p. 
10 – 20 mg/kg, 
b.i.d., i.p. 
Kimball et al. 
[96] 
C57BL/6 
mouse 
DSS 
 
IL-10 (-/-) 
JWH-133 CB2 10 – 20 mg/kg, 
q.d., i.p. 
2.5 mg/kg, 
q.a.d., i.p. 
Singh et al. 
[114] 
C57BL/6N 
mouse 
TNBS JWH-133 
 
AM1241 
CB2 
 
20 mg/kg, 
q.d./b.i.d., i.p. 
10 – 20 mg/kg, 
b.i.d., i.p. 
Storr et al. [105] 
C57BL/6 
mouse 
DSS Compounds 58 
and 64 
CB2 10 mg/kg, q.d., 
i.p. 
Tourteau et al. 
[133] 
 
Abbreviations: AEA: anandamide; b.i.d.: bis in die (twice daily); i.p.: intraperitoneally; q.a.d.: quaque altera die 
(every other day); q.d.: quaque die (once daily); s.c.: subcutaneously 
 
Modulation of intestinal barrier functions 
 
Epithelial damage and breach of the intestinal barrier are important factors in the pathomechanism of 
IBD, which allow bacterial products and other antigens to cross the epithelium and enter the lamina propria, 
resulting in inflammation and tissue damage [134-136]. Restoration of the barrier function therefore represents an 
important approach to treat IBD patients. In this respect, it is of relevance that the endocannabinoids AEA and 
noladin ether, as well as the CB1 receptor agonist arachidonylcyclopropylamide (ACPA), but not the CB2 receptor 
agonist JWH-133 induced wound-closure in human colonic epithelial cell lines [82], implying that CB1 receptor 
activation can improve the impaired mucosal barrier in IBD. This concept is underpinned by studies demonstrating 
that ∆9-THC and CBD prevented EDTA- and cytokine-induced increased paracellular permeability in the Caco-2 
cell culture model and increased the expression of the tight-junction protein zonula occludens 1, which effects 
were sensitive to CB1-, but not to CB2-antagonism [118, 137]. On the other hand, the latter studies also showed 
that apical, but not basolateral application of AEA and 2-AG exerted opposite effect, and increased Caco-2 cell 
permeability, which was also mediated by CB1 receptors and was at least partly due to down-regulated expression 
of claudin-1, another tight-junction protein [118, 137]. These in vitro results suggest that CB1 receptor ligands can 
induce opposing effects on inflammation-induced intestinal permeability and may initiate different signaling 
pathways, leading to changes in different tight junction proteins. The complex (and yet not fully understood) role 
of cannabinoids on intestinal permeability is also indicated by in vivo studies. Zoppi et al. [113], for example, 
provided evidence for the mucosal protective effect of the ECS, because immobilization and acoustic stress 
induced greater inflammation and colonic barrier dysfunction (characterized by lower IgA secretion, higher 
paracellular permeability to 51Cr-EDTA and higher bacterial translocation) in CB1 (-/-) mice. In contrast, the study 
of Muccioli et al. [138] suggests that CB1 receptor activation is rather detrimental for the epithelial barrier function, 
because the CB1 receptor antagonist SR141716A improved gut barrier functions and reduced gut permeability in 
obese ob/ob mice, while chronic (4-week) infusion of the CB1/CB2 agonist HU-210 increased gut permeability in 
lean wild-type mice. Thus, the accumulated evidence indicates that CB receptor ligands able to directly modulate 
intestinal epithelial permeability by acting mainly on CB1 receptors, but further studies are warranted to resolve 
the apparent contradictions reported thus far. It also has to be considered that the anti-inflammatory effect of 
cannabinoids can indirectly modify their action on intestinal permeability and improve barrier functions [98]. 
 
Inhibition of motility and secretion 
 
Beside their potent anti-inflammatory property and modulatory effect on intestinal epithelial 
permeability, cannabinoids also inhibit gastrointestinal motility and secretion, which both may alleviate diarrhea, 
a common clinical manifestation of IBD [139, 140]. 
The effect of cannabinoids on gastrointestinal motility is well-documented and has been extensively 
reviewed [117, 139, 141]. A large amount of data obtained from in vitro and in vivo studies demonstrate that 
activation of presynaptic CB1 receptors by cannabinoids and endocannabinoid degradation inhibitors reduces 
gastrointestinal smooth muscle contractility, gastric emptying and intestinal peristalsis in both animals and 
humans. This effect is mainly due to presynaptic inhibition of acetylcholine release from cholinergic nerves, but 
additional mechanisms, such as inhibition of non-adrenergic-non-cholinergic excitatory and inhibitory 
transmission have also been described [142-144]. Furthermore, the results of Grider et al. [145] suggest that CB1 
receptors inhibit all components of the peristaltic reflex in the rat colon, namely the excitatory 
cholinergic/tachykininergic motor neurons, the inhibitory VIPergic motor neurons as well as the intrinsic sensory 
CGRP-containing neurons. 
Regarding the inhibitory action of cannabinoids on GI motility, two important differences have been 
described between normal and inflamed tissues. First, CB1 receptor-mediated suppression of motility is enhanced 
during inflammation, which is mirrored by lower ED50 values of cannabinoids in croton oil-treated mice [91, 146]. 
This phenomenon may result (at least partly) from the overexpression of CB1 receptors, which was reported by 
several groups (see above). Second, although under physiological conditions GI motility is predominantly 
regulated by CB1 receptors [117], in inflammation CB2 receptors are also involved in the control of (pathological) 
motility. The importance of CB2 receptors in inflammatory state is indicated by studies showing that JWH-133, a 
selective CB2 receptor agonist normalized the lipopolysaccharide (LPS)-induced intestinal hypermotility both in 
vitro [86] and in vivo [147]. Because CB2 receptors are upregulated in epithelial cells during inflammation and 
also abundantly expressed by immune cells, their activation may effectively reduce the release of various 
inflammatory mediators from these cells, which would otherwise stimulate intestinal peristalsis. 
Another important feature of cannabinoids is that they also decrease intestinal secretions, which may take 
part in their antidiarrheal action. This effect is predominantly, if not entirely mediated by CB1 receptors and was 
observed both in vivo [140] and in vitro [116, 148, 149]. The latter studies clearly demonstrated that cannabinoids 
act on the enteric nerves and not on the epithelium, because the cannabinoid agonist WIN 55,212-2 inhibited ileal 
secretions caused by electrical stimulation and capsaicin, but not by acetylcholine, carbachol or forskolin [116, 
149]. Moreover, the colocalization of CB1 and TRPV1 receptors, and the loss of inhibitory effect in extrinsically 
denervated ileal segments suggest that CB1 receptors controlling intestinal secretions are primarily localized on 
extrinsic primary afferent nerves that innervate submucosal secretomotoneurons [116]. 
 
Inhibition of visceral hypersensitivity 
 
Beside inhibiting motility and secretion cannabinoids may possess another important beneficial effect in 
IBD, namely alleviation of visceral hypersensitivity and abdominal pain. The analgesic effect of cannabinoids is 
well-described, especially in the case of somatic pains (for reviews see [150-153]), and several lines of evidence 
suggest that they also potently reduce visceral sensations. Both CB1 and CB2 receptor agonists were shown to 
reduce basal visceral sensitivity, as well as colitis-induced hypersensitivity to colorectal distension in rats and mice 
[115, 154-156]. In inflammation the antinociceptive effect of CB receptor agonists was enhanced [115], which is 
in accordance with their increased inhibitory effect on GI motility and may reflect the overexpression of the CB 
receptors during inflammation. The exact site of this visceral antinociceptive action still remains to be established, 
but some evidence points to the importance of peripheral CB receptors. For example, the peripherally restricted 
CB1/CB2 receptor ligand SAB-378 inhibited pain-related responses to colorectal distension similarly to WIN 
55,212-2 (which readily penetrates the blood-brain barrier) [154], and LPS- and bradykinin-evoked activation of 
mesenteric afferents was attenuated by CB1- and CB2-receptor stimulation, respectively [157, 158]. Increased 
epithelial expression of CB2 receptors due to oral administration of the Lactobacillus acidophilus NCFM also 
resulted in reduced visceral perception [159], but it is still not clear, exactly how these epithelial receptors influence 
the activity of nociceptive pathways. In short, these preclinical data suggest that cannabinoids may serve as useful 
tools for alleviating visceral hypersensitivity and relieving abdominal pain in IBD, and this assumption is 
supported by preliminary clinical studies, in which IBD-patients treated with cannabis reported a statistically 
significant pain reduction [109, 160]. 
 
Approaches to avoid central, CB1 receptor-mediated psychotropic effects 
 
On the one hand, cannabinoids effectively reduce intestinal inflammation and several accompanying 
symptoms, as discussed above. On the other hand, they can induce adverse psychotropic side effects, including 
anxiety, panic attacks, paranoia and cognitive impairment, which are primarily mediated by central CB1 receptors 
and hamper their utilization in the therapy [161]. 
In order to exploit the beneficial effects of cannabinoids and avoid their unacceptable side effects, four 
different therapeutic strategies could be pursued. 
 Selective activation of CB2 receptors 
 
The first, and probably most evident approach is the selective stimulation of CB2 receptors, which does 
not induce psychoactive effects [151], in spite of the presence of functional CB2 receptors within the central 
nervous system [48, 162]. As depicted above, CB2 receptors are abundant on immune cells, their intestinal 
expression is increased in inflammation and their activation significantly ameliorates the development of colitis in 
numerous animal models [96, 105, 114, 133]. Moreover, CB2 receptor agonists also suppress the inflammation-
induced hypermotility [86, 147] and visceral hypersensitivity [115, 155-157]. These data, obtained mainly from 
animal experiments, foreshadow an important role of CB2 receptor agonists in the therapy of IBD, but future trials 
are warranted to confirm their clinical efficacy and safety. 
 
Selective activation of peripheral CB receptors 
 
Another obvious approach to avoid central side effects is to use peripherally restricted drugs. Studies 
using either such compounds (e.g. SAB-378) or centrally acting drugs together with vagotomy or ganglionic 
blockade demonstrated that selective activation of peripheral CB receptors is sufficient to control both visceral 
nociception [154], intestinal motility [62, 91, 131] and secretions [140]. An important question is, however, 
whether the inflammation itself can also be inhibited by selective peripheral CB receptor modulation. The intestinal 
localization of the ECS and the increased expression of CB receptors and endocannabinoids in inflammation imply 
that peripheral CB receptors play an important, if not predominant, role in the regulation of inflammatory 
processes. Interestingly, the results of two recent studies suggest the opposite. Cluny et al. [131] reported that 
intraperitoneal application of SAB-378 did not influence DSS- or TNBS-induced colitis in mice, which was later 
confirmed by Fichna et al. [128]. In contrast, i.c.v. administration of the same compound afforded protection 
against TNBS [128]. These findings suggest that centrally located CB receptors are crucial for the anti-
inflammatory action of cannabinoids, and also question the feasibility of this second strategy in the IBD therapy. 
On the other hand, it is worthy of note that SAB-378 was used in a relatively low dose range (0.1 – 1 mg/kg), as 
compared to the anti-inflammatory doses of several other CB receptor ligands (see Table 4), and it can be raised 
that higher doses could be protective without inducing relevant central effects. The potential inability of 
peripherally restricted cannabinoids to inhibit intestinal inflammation is therefore yet to be confirmed. 
 
Increasing the level of endocannabinoids 
 
As mentioned before, pharmacological or genetic blockade of either CB1 [95], or CB2 [105, 163] or both 
receptors [99] aggravated the inflammatory reaction in various colitis models, suggesting the existence of an 
endogenous cannabinoid tone, which confers protection against an inflammatory insult. Thus, boosting the on-
demand (intestinal) synthesis of endocannabinoids and/or preventing their degradation theoretically offers the third 
possibility to harness the CB receptor-mediated beneficial effects and avoid (or minimize) the undesired central 
psychotropic effects [52]. 
Indeed, a number of studies have shown that elevating the level of AEA or 2-AG by inhibiting the AEA 
uptake mechanism, or their major degrading enzymes FAAH and MAGL results in significant protection against 
colitis in mice (Table 4). Although these studies did not directly address the analysis of potential central side 
effects, other studies demonstrated that URB 597 [164] or JZL 184 [165] do not produce antinociception, catalepsy 
or hypothermia in the same dose range. 
Beside inhibiting the inflammation, MAGL inhibitors also improved intestinal barrier functions and 
delayed GI transit, [94, 98], while the AEA uptake inhibitor VDM 11 reduced visceral hypersensitivity by 
modulating the firing of intestinal afferent nerves [158]. These findings together corroborate the concept that 
modulation of the ECS might be a promising way to treat IBD. 
Finally, it is worthy of note that the FAAH inhibitors URB 597 and AA-5-HT were less effective than 
the uptake inhibitor VDM 11 to elevate the intestinal level of AEA, to decrease intestinal inflammation [92] and 
to suppress the activity of intestinal afferents [158], which suggests that the effect of AEA is mainly terminated 
by uptake rather than FAAH-mediated breakdown in the GI tract. 
 
Table 5. Elevating the level of endocannabinoids alleviates murine colitis 
 
Animal Colitis model Target of block Drug Dosage and 
route of 
administration 
Reference 
C57BL/6N 
mouse 
DNBS FAAH -  
(genetic 
deletion) 
- Massa et al. [95] 
CD1 mouse DSS 
TNBS 
FAAH  
(+ COX-1, COX-
2) 
ARN2508 1 – 30 mg/kg, 
q.d., p.os 
Sasso et al. [40] 
C57BL/6J 
mouse 
DNBS AEA uptake 
 
FAAH 
VDM 11 
 
AA-5-HT 
5 mg/kg, q.d., 
s.c. 
10 mg/kg, q.d., 
s.c. 
D'Argenio et al. 
[92] 
C57BL/6N 
mouse 
TNBS AEA uptake 
 
FAAH 
VDM 11 
 
URB 597 
5 mg/kg, 
q.d./b.i.d., i.p. 
5 mg/kg, 
q.d./b.i.d., i.p. 
Storr et al. [97] 
C57BL/6 
mouse 
TNBS FAAH compound 39 10 mg/kg, q.d., 
i.p. 
Andrzejak et al. 
[166] 
C57BL/6 
mouse 
DSS FAAH compounds 10 
and 11 
10 mg/kg, q.d., 
i.p. 
Tourteau et al. 
[167] 
C57BL/6 
mouse 
TNBS MAGL JZL 184 16 mg/kg, 
b.i.d., i.p. 
Alhouayek et al. 
[98] 
C57BL/6 
mouse 
TNBS FAAH PF-3845 10 mg/kg, q.d., 
i.p. 
Alhouayek et al. 
[33] 
C57BL/6 
mouse 
TNBS FAAH PF-3845 10 mg/kg, 
q.d./b.i.d., i.p., 
i.c., p.os 
Salaga et al. 
[106] 
 
Abbreviations: 2-AG: 2-arachidonoylglycerol; AEA: anandamide; b.i.d.: bis in die (twice daily); COX: 
cyclooxygenase; ECS: endocannabinoid system; FAAH: fatty acid amide hydrolase; i.c.: intracolonically; i.p.: 
intraperitoneally; MAGL: monoacylglycerol lipase; p.os: orally; q.d.: quaque die (once daily); s.c.: subcutaneously 
 
Using non-psychotropic phytocannabinoids 
 
The fourth approach to minimize cannabimimetic effects is the use of various phytocannabinoids, such 
as CBD, CBG or CBC. In general, these compounds exert multiple pharmacodynamic actions, which are not or 
only partially related to modulation of the ECS (see the review of [124]). CBD does not activate CB1 and CB2 
receptors (or even antagonizes them), but inhibits or activates several enzymes, transporters or receptors, including 
FAAH (inhibitor), the AEA and adenosine transporters (inhibitor), PPAR-γ receptor (agonist) or TRPV1 (agonist) 
[124]. CBD possessed potent anti-inflammatory action in DNBS-, TNBS and LPS-induced intestinal inflammation 
in mice and rats [93, 122, 130, 168], as well as in human colonic cultures derived from UC patients, in which 
PPAR-γ was identified as a key receptor [122]. In addition, CBD was also shown to inhibit inflammation-induced 
hypermotility [169] which, together with the anti-inflammatory action, the lack of psychotropic activity and low 
toxicity [170], makes it a promising candidate for the treatment of IBD. 
Another promising phytocannabinoids are CBG and CBC: the first is a partial agonist of CB1 and CB2 
receptors as well as an AEA reuptake inhibitor [124], which exerted both preventive and curative effects in DNBS-
induced colitis, and also attenuated both nitrite production in macrophages and ROS production in intestinal 
epithelial cells [171], while CBC is a potent TRPA1 agonist and weak anandamide reuptake inhibitor, which also 
ameliorated DNBS colitis in mice [172] and reduced croton oil-induced increased motility [89]. 
 
SUMMARY AND CONCLUSIONS 
 
The cannabinoid receptors, the endocannabinoids AEA and 2-AG, and proteins responsible for their 
synthesis and degradation are widely distributed in the GI tract and several data suggest that their expressions are 
substantially altered during inflammatory processes. Consequently, the ECS can be a potential target to reduce the 
gastrointestinal mucosal lesions, hemorrhage and inflammation. Direct activation of CB1 receptors by plant-
derived, endogenous or synthetic cannabinoids effectively reduces gastric acid secretion, gastric motor activity, 
formation of gastric mucosal lesions induced by stress, pylorus ligation, NSAIDs or alcohol, as well as inhibits 
intestinal inflammation in different murine colitis models. While the gastric protective effect is likely to be 
mediated by CB1 receptors, involvement of both CB1 and CB2 receptors was shown to inhibit intestinal 
inflammation. Moreover, indirect activation of cannabinoid receptors through elevation of endocannabinoid levels 
by inhibition of their metabolizing enzymes (FAAH, MAGL) or cellular uptake reduced the gastric mucosal lesions 
induced by NSAIDs and intestinal inflammation in colitis models. 
However, besides their beneficial effects on gastrointestinal ulcerative and inflammatory conditions, 
cannabinoids may induce several adverse effects, first of all the central CB1 receptor-mediated psychotropic 
effects. Several attempts have been made to develop CB receptor ligands which devoid of central psychotropic 
effects, such as peripherally acting ligands, CB2 receptor selective compounds, or inhibitors of degradation or 
uptake of endocannabinoids. On the other hand, it also should be considered that activation of central CB1 or CB2 
receptors may also contribute to some beneficial effects of cannabinoids. Or selective CB2 receptor activation can 
alleviate intestinal inflammation, but may not influence the development of gastric mucosal damage. In addition, 
elevation of the tissue levels of endocannabinoids may increase the formation of cyclooxygenase-, lipoxygenase- 
and cytochrome P450-derived metabolites, which are bioactive and may have pro-inflammatory properties as well. 
In spite of these concerns, the numerous experimental data and preliminary clinical studies are convincing, and 
the ECS represents a promising target in the treatment of inflammatory bowel diseases and gastric mucosal lesions, 
ulceration and inflammation. The intensive research focusing to develop new structures that modulate the ECS 
without inducing the central undesired side effects, gives the hope that in the near future safe, effective 
compound(s) could be translated into clinical praxis. 
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